MedTrace Logo

Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors

NCT01679470 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2016-11-03

No results posted yet for this study

Summary

This is an open-label, single-center, single-dose efficacy pilot study of AuroLase Therapy in the treatment of subjects with primary and/or metastatic tumors of the lung where there is airway obstruction. In this study patients will be given a systemic IV infusion of particles and a subsequent escalating dose of laser radiation delivered by optical fiber via bronchoscopy.

Conditions

  • Primary or Metastatic Lung Tumors

Interventions

DEVICE

AuroLase Therapy

Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.

Sponsors & Collaborators

  • Nanospectra Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Glenn Goodrich, PhD · Nanospectra Biosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01679470 on ClinicalTrials.gov